2cureX EBIT per Share

What does 2cureX do? 2cureX AB develops anti-cancer treatments through research and development, focusing on diagnostic substances to optimize cancer patient care. Its key product, IndiTreat - CRC, enables healthcare professionals to test chemotherapies and experimental treatments using three-dimensional micro tumors created from patient tumor samples. The company also offers IndiTreat - OVA for ovarian cancer and IndiTreat - KDN for kidney cancer, forming its product pipeline. 2cureX AB operates through 2cureX A/S, targeting healthcare providers and oncology specialists who seek personalized treatment solutions for cancer patients. The company generates revenue by providing diagnostic services and product candidates to healthcare institutions. IndiTreat - CRC, IndiTreat - OVA, and IndiTreat - KDN are sold as diagnostic tools to hospitals and clinics specializing in cancer treatment. These products help medical teams select the most effective therapies for individual patients, reducing trial-and-error in cancer care. 2cureX AB's business model relies on the adoption of its diagnostic platform by oncology departments seeking precision medicine approaches. 2cureX AB's primary customers are healthcare professionals and institutions involved in cancer treatment, particularly those focused on colorectal, ovarian, and kidney cancers. The firm's diagnostic solutions are used to guide treatment decisions, with IndiTreat - CRC being the most advanced product in its pipeline. By offering tailored diagnostic services, 2cureX AB supports healthcare providers in delivering targeted therapies, aligning with the growing demand for personalized cancer care strategies. 2cureX is one of the most popular companies on Eulerpool.